Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eVOLVE-Cervical phase 3 study of volrustomig after chemoradiotherapy in high-risk locally advanced cervical cancer
CTR20250226Phase 3Active
- Sponsor
- AstraZeneca
- Start
- May 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of volrustomig in Cervical Cancer (CC), sponsored by AstraZeneca. Started May 2025; status: active.
02
Drugs
volrustomig
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20250226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250226.